GO Therapeutics

GO Therapeutics is the only company with the technology, platform, and expertise to harness the power of the cancer glycoproteome for generating specific tumor-targeting antibodies for cancer immunotherapy. By combining antibodies targeting hybrid antigens with the upregulated protein expression of tumors and abnormal glycosylation patterns of proteins, the company can significantly enhance tumor specificity. The company’s technology overcomes the barriers to manufacturing drugs that are highly specific to cancer cells.